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Abstract
The aim of the study is to know the effectiveness of clomiphene citrate and letrozole for ovulation   
related to endometrial thickness and number of dominant follicle. Study design was cross sectional based 
on medical records of women who underwent ovulation induction from January 2011-May 2015. A number 
of 143 anovulation women were divided into clomiphene citrate 50mg, clomiphene citrate 100 mg, letrozole 
2.5mg and letrozole 5mg. Each group received the agent daily on 3rd-7th day of menstrual cycle. On 12th 
day of menstrual cycle, the transvaginal ultrasound was performed to measure endometrial thickness and 
dominant follicle number. From all subjects, 45 subjects (31.5%) were in 50mg clomiphene citrate groups, 29 
subjects (20.3%) in 100mg clomiphene citrate group, 23 subjects (16.1%) in 2,5mg letrozole group, and 46 
subjects (32.2%) in 5mg letrozole group. Subjects who received letrozole had thicker endometrium compared 
to clomiphene citrate (p<0.05). Different doses were not associated with endometrial thickness between 
subjects who received either letrozole or clomiphene citrate. In addition, subjects receiving letrozole had 
higher proportion of having trilaminar endometrium morphology. We did not observe the difference in total 
number of dominant follicle between groups. It is concluded that letrozole is more effective than clomiphene 
citrate in terms of endometrial thickness but not for number of dominant follicles.  
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Efektivitas Induksi Ovulasi Klomifen Sitrat dan Letrozol dalam Hal Ketebalan 
Endometrium dan Jumlah Folikel Dominan
Abstrak
Studi ini bertujuan untuk menilai efektivitas induksi ovulasi klomifen sitrat dan letrozol dalam hal 
ketebalan endometrium dan jumlah folikel dominan pada perempuan yang tidak berovulasi.  Desain studi 
adalah potong lintang menggunakan rekam medik pasien yang menjalani induksi ovulasi pada bulan Januari 
2011-Mei 2015. Sebanyak 143 perempuan yang tidak berovulasi dibagi dalam kelompok yang mendapat 
klomifen sitrat 50mg, klomifen sitrat 100mg, letrozol 2.5mg dan letrozol 5mg.  Setiap kelompok mendapat 
obat induksi ovulasi antara hari ke-3 sampai hari ke-7 siklus haid.  Pada hari ke-12 siklus haid dilakukan 
ultrasonografi transvaginal untuk mengukur ketebalan endometrium dan jumlah folikel dominan. Sebanyak 
45 subyek (31,5%) mendapat klomifen sitrat 50mg, 29 subyek (20,3%) mendapat klomifen sitrat 100mg, 
23 subyek (16,1%) mendapat letrozol 2,5mg dan 46 subyek (32,2%) mendapat letrozol 5mg.  Subyek yang 
mendapat letrozol memiliki endometrium yang lebih tebal dibandingkan kelompok klomifen sitrat (p<0,05).  
Dosis yang berbeda tidak berhubungan dengan ketebalan endometrium baik pada kelompok klomifen sitrat 
maupun letrozol. Kelompok yang mendapat letrozol lebih banyak memiliki gambaran morfologi endometrium 
trilaminar. Tidak dijumpai perbedaan bermakna dalam jumlah folikel di antara semua kelompok. Disimpukan 
letrozol lebih efektif dibandingkan klomifen sitrat dalam hal ketebalan endometrium tetapi tidak untuk jumlah 
folikel dominan.
Kata kunci:  klomifen sitrat, letrozol, induksi ovulasi, ketebalan endometrium, folikel dominan.
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World Health Organization (WHO) had declared 
infertility as a health problem on 30th November 
2009. Infertility has a definition as a reproductive 
system disease marked by the inability of achieving 
pregnancy after 12 months or more periods of sexual 
intercourses without the use of contraception.1,2 It 
occured on about 10-15% spouses at reproductive 
age in the United States (6% in North America and 
3.1% in South & Middle America), 3% in Middle East, 
10.1% in Africa, 4.8% in Asia and Oceania, 2.9% in 
India, 2.9% in Philippines, 1.9% in Bangladesh, and 
3.4% in Indonesia.3-5
Infertility caused by female factors accounted 
for 28.6% to 57.5% of all cases.6-10 WHO 
explained that anovulation infertility caused by 
ovulation dysfunction (WHO anovulation infertility 
classification class 2) appeared on 80% of cases.11 
One of the treatment to cure this condition is by 
ovulation induction to stimulate mature oocyte.12 All 
this time, ovulation induction agent commonly used 
in Indonesia is clomiphene citrate. It has a relatively 
high ovulation success rate, approximately 50-
75%, but the conception success rate is just about 
10-40%.13-15 The unconformity between ovulation 
and conception rate of this drug is caused by the 
anti-estrogen effect of clomiphene citrate which 
caused the thinning of endometrium layer and 
reducing endometrium exogenicity.15-20 Dehbashi et 
al16 reported that the administration of clomiphene 
citrate affected endometrium thickness, but 
not its exogenicity. Gonen et al17 found that the 
administration of clomiphene citrate was actually 
affecting endometrium thickness and exogenicity, 
and there was a conformity between endometrial 
thickness, exogenicity, and pregnancy rate. A study 
by Rinaldi et al18 concluded that pregnancy rate was 
higher in the group with an endometrium thicker 
than 10 cm. Therefore, the anti-estrogen effect of 
clomiphene citrate was suspected as the cause of 
the ovulation-conception number unconformity.15
The other promising ovulation inducing agents 
other than clomiphene citrate is letrozole. Letrozole 
is an aromatase inhibitor commonly used in breast 
cancer treatment. Aromatase inhibitor reduces 
estrogen level in breast cancer patients and inhibiting 
the growth of the cancer.21 The use of letrozole as 
an ovulation inducing agents is promising and will 
improve ovulation-conception rate unconformity 
found on clomiphene citrate administration because 
letrozole has no anti-estrogen effect like clomiphene 
citrate.15 Begum et al22 proved that the endometrial 
layer was thicker on letrozole administration 
compared to clomiphene citrate (9.03±0.89mm 
vs 10.37±1.2mm; p<0.05). However, there were 
different results such as the study by Badawy 
et al,24 obtaining different result on endometrial 
thickness between clomiphene citrate and letrozole 
(9.2±0.7mm vs 8.1±0.2mm; p<0.05). Disappointing 
result was also reported by Dehbashi et al,23 where 
the endometrial thickness on either clomiphene 
citrate and letrozole did not show any significant 
difference (7.12±2.01mm vs 6.44±1.68mm; p>0.05). 
Although there were differences on endometrial 
thickness, letrozole is still considered as a promising 
drug because of the absence of anti-estrogenic 
effect. Therefore, this study is aimed to know the 
effectiveness of clomiphene citrate and letrozole for 
ovulation induction related to endometrial thickness 
and the number of dominant follicles between the 
administration of 50mg to 100mg of clomiphene 
citrate with 2,5mg to 5mg of letrozole.
 
Methods
This is a cross sectional study using medical 
records of patients receiving either 50mg clomiphene 
citrate, 100mg clomiphene citrate, 2.5mg letrozole, 
or 5mg letrozole at dr. Cipto Mangunkusumo 
National Hospital, Jakarta from January 2011–
May 2015. Every treatment groups received the 
agent daily on 3rd-7th day of menstrual cycle. The 
inclusion criteria of the samples were women who 
met the diagnostic criteria for anovulation infertility, 
receiving either 50 mg clomiphene citrate, 100mg 
clomiphene citrate, 2.5mg letrozole or 5mg letrozole 
therapy, and have a complete USG medical record. 
On 12th day of menstrual cycle, transvaginal 
ultrasound examination was performed to measure 
endometrial thickness and dominant follicle number. 
Ultrasonography examination was performed by 
expert in reproductive endocrinology. Smokers 
and patients receiving both clomiphene citrate and 
letrozole at the same time were excluded. 
All numerical values were tested for their 
distribution normality using Kolmogorov-smirnov or 
Shapiro-wilk tests. Normally distributed data were 
expressed as mean ± standard deviation whereas 
non-normally distributed data were expressed as 
median (minimum-maximum). The comparison 
of numerical variables between groups were 
tested using one-way ANOVA and Kruskall Wallis. 
Independent t-test or Mann-Whitney were used for 
post-hoc analysis between groups. All p values <0.05 
were considered statistically significant. Statistical 
analysis were performed using Statistical Package 
for Social Science (SPSS) for windows version 22.
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License to use the medical records of patients 
at RSCM had been coordinated with related parties 
and had been approved by the Health Research 
Ethics Committee of the Faculty of Medicine, 
Universitas Indonesia Number 245 / UN2.F1 / ETIK 
/ 2015 on 30 March 2015.
Results
Subjects’ Characteristics
A number of 143 patients were recruited in 
this study. Subjects were grouped based on their 
treatment: 45 patients on clomiphene citrate 50mg 
group, 29 patients in clomiphene citrate 100mg 
group, 23 patients in letrozole 2.5mg group, and 46 
patients in letrozol 5mg group. Characteristics of the 
subjects were presented in Table 1. We classified 
patient’s causes of infertility either male, female or 
idiopathic factor as shown in Table 2. There was no 
difference in causes of infertility in four groups.
Table 1.  Subject Characteristics between Groups Received Clomipheneand Letrozole 
(n=143)
Characteristics Clomiphene
50mg (n=45)          100mg (n=29)
Letrozole
2.5mg (n=23)          5mg (n=46)
Age (year) 33.29 ±4.5 33.76 ± 5.24 34.97 ± 5.1 34.11 ± 4.06
BMI (kg/m2) 22.2 (17.7-40.1) 23.63 ± 3.77 23.9 ± 3.47 23.1 ± 3.47
Duration of 
infertility (year) 3 (1-13) 3 (1-13) 5 (1-10) 3 (1-13)
Data were presented as mean ± standard deviation or median (minimum-maximum)
Table 2. Etiology of Infertility between Groups Received Ovulation Induction
Etiology Clomiphene50mg (n=45)               100mg (n=29)
Letrozole
2,5mg (n=23)        5mg (n=46)
Male factor 11 (24.4%) 7 (24.1%) 8 (34.8%) 17 (37.0%)
Female factor 18 (40.0%) 6 (20.7%) 8 (34.8%) 14 (30.4%)
Idiopathic 16 (35.6%) 16 (55.2%) 7 (30.4%) 15 (32.6%)
Endometrial Thickness, Morphology, and 
Number of Dominant Follicle 
There was a significant difference on endometrial 
thickness on late-follicular phase (p<0.001) between 
women receiving clomiphene citrate and letrozole. 
However, there were no significant differences on 
the comparison of women receiving 2.5mg letrozole 
against women receiving 5mg letrozole and between 
women receiving 50mg clomiphene citrate and 
100mg clomiphene citrate (p>0.005). 
Trilaminar endometrial morphology was higher in 
women receiving 2.5mg and 5mg letrozole compared to 
those administered with 50mg and 100mg clomiphene 
citrate (14% and 23.1%). There was no significant 
difference on follicle numbers between women receiving 
clomiphene citrate and letrozole (Table 3).
Table 3.  Endometrial Thickness, Morphology, and Number of Dominant Follicle after Ovulation 
Induction
Outcome Variables Clomiphene Letrozole
50mg (n=45)   100mg (n=29) 2,5mg (n=23) 5mg (n=46)     p
Endometrial thickness (mm)a,b,c,d 9 (5-20) 8 (4.3-17) 12 (11-16) 11 (8-18) <0.001*
Number of dominant follicle (n,%) 1 (0-3) 1 (0-2) 1 (1-2) 1 (0-3) 0.664
Endometrial morphology (n,%)
   Thin 14 (9.8%) 4 (2.8%) 0 1 (0.7%) <0.001
   Intermediate 13 (9.1%) 12 (8.4%) 3 (2.1%) 12 (8.4%)
   Trilaminar 18 (12.6%) 13 (9.1%) 20 (14%) 33 (23.1%)
*Kruskal Wallis 
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Post-hoc analysis with Mann-Whitney test with 
p<0.05 between: aclomiphene citrate 50mg dan 
letrozole 2.5mg, baclomiphene  50mg and letrozole 
5mg, caclomiphene  100mg and letrozole 2.5mg, 
and daclomiphene  100mg and letrozole 5mg.  
Discussion
This study compared endometrial thickness, 
morphology, and number of dominant follicle 
between groups receiving different doses of 
either clomiphene citrate or letrozole. This study 
confirmed the difference of endometrial thickness 
and endometrium morphology between these two 
different type of induction agents. This was similar 
with previous study: letrozole yielded thicker 
endometrium, thus preferable for successful 
pregnancy.22 However, a contrary result was noted 
from Maryati et al24 study among Indonesian 
population with similar setting. Besides, Casper 
and Mitwally25 reported that there was no difference 
in the number of dominant follicle between groups. 
To date, clomiphene citrate is the most 
prescribed induction agent. However, there was a 
rising question about its efficacy. Although ovulation 
rate was quite high, the pregnancy rate was still low. 
This probably due to endometrial thickness and 
nontrilaminar morphology. Letrozole has become a 
center of attention as it has anti-estrogenic effect.26
This study found that there was no difference in 
the given doses of induction agent. Previous report by 
Fadhli et al27 found a thicker endometrium with 5mg 
letrozole compared to 2.5mg letrozole. Previously, 
successful rate in pateints who took letrozole was 
higher than clomiphene citrate. As clomiphene 
citrate remains a gold standard for therapy, Begum 
et al22 found that letrozole could become a solution if 
they failed with clomiphene citrate. 
Endometrial thickness is an important factor 
for successfull pregnancy after induction. However, 
there is a controversy on its role due to different 
results in many trials. In a meta-analysis, there was 
no difference in pregnancy rate and ovulatory cycles 
between letrozole and clomiphene citrate.28Remohi 
et al29 stated that estradiol level correlated 
with endometrial thickness. Also, endometrial 
thickness correlated with implantation. However, 
those parameters were not a good predictors for 
pregnancy. There were another factors attributed 
for successful pregnancy, including vasculature 
of the subendometrium and intraendometrium.30 
The main limitation encountered in this study was 
unequal sample size between all groups. Besides, 
we could not report the effects of each treatment 
regarding with the neonatal outcomes.
Conclusions
This study supported that letrozole was 
associated with thicker endometrium and trilaminar 
morphology of endometrium. However, there 
was no significance difference in the number of 
dominant follicle. Further study on its efficacy 
toward pregnancy rate between different doses of 
clomiphene citrate and letrozole among Indonesian 
population is needed.
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